Abstract: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.
Type:
Grant
Filed:
April 24, 2006
Date of Patent:
November 10, 2009
Assignee:
Morphotek, Inc.
Inventors:
Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
Abstract: Inhibitors of the MAPK pathway, including MEK-directed proteases and small molecule inhibitors, are cytotoxic to human melanoma cells in vitro and in vivo via apoptotic mechanisms. These compounds are used to kill melanoma cells and to treat subjects with melanoma, either alone or in combination with other therapeutic modalities.
Type:
Grant
Filed:
June 20, 2005
Date of Patent:
November 3, 2009
Assignee:
Van Andel Research Institute
Inventors:
Han-Mo Koo, Eunmi (Kay) Koo, legal representative, George F. Vande Woude, Nicholas S. Duesbery
Abstract: The invention provides novel STAMP2 nucleic acid molecules, polypeptides, antibodies, and modulatory compounds for use in methods of diagnosing, treating, and preventing diseases and conditions of the prostate and testis, such as cancer.
Type:
Grant
Filed:
June 15, 2006
Date of Patent:
November 3, 2009
Assignee:
President and Fellows of Harvard College
Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.
Type:
Grant
Filed:
March 13, 2007
Date of Patent:
November 3, 2009
Assignee:
Celera Corporation
Inventors:
Elizabeth G. Joseloff, Yeoun Jin Kim, Tao He, Steve Ruben
Abstract: The invention features anti-idiotype antibodies of the human monoclonal antibody SC-1, as well as methods for producing and using the anti-idiotype antibodies.
Type:
Grant
Filed:
November 15, 2004
Date of Patent:
November 3, 2009
Assignee:
Debiovision
Inventors:
Heinz Peter Vollmers, Hans Konrad Müller-Hermelink
Abstract: The present invention provides novel peptides, nucleic acids, vectors, compounds, compositions and methods for regulating nuclear import. The present invention also relates to a lentiviral NLS, and methods of use thereof for inhibiting HIV pathogenesis and disease progression, and for gene delivery methods.
Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.
Type:
Grant
Filed:
December 13, 2004
Date of Patent:
October 20, 2009
Assignee:
Centocor, Inc.
Inventors:
G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Ngo
Abstract: The present invention relates to multivalent HIV inhibitors that bind to multiple sites on a trimeric gp120 complex thereby blocking the CD4 binding site on the trimeric gp120 complex and inhibiting the attachment and entry of HIV through gp120-CD4 interactions.
Type:
Grant
Filed:
February 9, 2005
Date of Patent:
October 20, 2009
Assignee:
University of Maryland Biotechnology Institute
Abstract: The present invention provides screening methods for identifying BRM expression-promoting histone deacetylase (HDAC) inhibitors, diagnostic methods for determining the suitability of treatment of a candidate subject with a BRM expression-promoting HDAC inhibitor, and therapeutic methods for treating cancer cells in a patient with a BRM expression-promoting HDAC inhibitor. The present invention also provides BRG1 and BRM diagnostics, methods for increasing a cancer patient's resistance to viral infection, and methods for determining the suitability of treatment of a candidate subject with a glucocorticoid compound or retinoid compound.
Type:
Grant
Filed:
March 1, 2006
Date of Patent:
October 20, 2009
Assignee:
The Regents of the University of Michigan
Abstract: The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. The present inventors discovered that there are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore the inventors applied the discovery to diagnosis and found that colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No.
Type:
Grant
Filed:
July 9, 2004
Date of Patent:
October 13, 2009
Assignees:
Japan Science & Technology Agency, Local Government of Aichi Prefecture, Wako Pure Chemical Industries, Ltd.
Abstract: A novel prostate cancer marker is described that is found in cancerous and normal prostate cells of individuals that have prostate cancer but is not found in the prostate of individuals without prostate cancer. The marker also is present in normal tissue adjacent to tumor tissue in individuals having prostate cancer. The marker, however, is absent in the prostate of individuals without prostate cancer. Methods employing the novel prostate cancer marker of the invention to predict the occurrence of the prostate disease, monitor the progression of prostate cancer and effect the treatment of prostate cancer, also are described.
Type:
Grant
Filed:
March 1, 2004
Date of Patent:
October 6, 2009
Assignee:
University of Pittsburgh of the Commonwealth System of Higher Education
Abstract: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating cellular proliferation disorders and cellular motility disorders. In particular, the present invention provides compositions and methods for using CXCL chemokines (e.g., CXCL1, CXCL5, CXCL6, CXCL12), CXCL receptors (e.g., CXCR1, CXCR2, CXCR4, CXCR7), and/or pathway related compounds (e.g., NF-kappaB, ERK ½, ELK-1) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy, prostatitis).
Type:
Grant
Filed:
November 28, 2007
Date of Patent:
October 6, 2009
Assignee:
The Regents of the University of Michigan
Abstract: The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
Type:
Grant
Filed:
October 29, 2004
Date of Patent:
October 6, 2009
Assignees:
Burnham Institue for Medical Research, The Regents of the Universtiy of California
Inventors:
Douglas Hanahan, Erkki Ruoslahti, Johanna A. Joyce, Pirjo Laakkonen
Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer.
Type:
Grant
Filed:
March 8, 2007
Date of Patent:
October 6, 2009
Assignee:
The Regents of the University of Michigan
Inventors:
Arul Chinnaiyan, David Beer, Guoan Chen, Xiaoju Wang
Abstract: A method is provided for detecting an analyte indicative of a cancer or a metastatic disease condition, which utilizes the ability of the analyte to induce permeability in a barrier. The method includes providing a biosensor having a barrier which is substantially impermeable to an ion, a permeable membrane which is selective for the ion, and a detector capable of detecting the ion. The biosensor is contacted with a sample including at least one of the ion and the analyte, wherein the analyte causes at least a portion of the ion to pass through the barrier and the membrane. Passage of the ion through the barrier and membrane allows detection of the ion, providing indirect detection of the analyte. In one embodiment, the barrier is a cell monolayer, the membrane is selective for potassium, and the analyte is vascular endothelial cell growth factor.
Type:
Grant
Filed:
November 8, 2005
Date of Patent:
September 29, 2009
Assignee:
University of Kentucky Research Foundation
Inventors:
Kimberly W. Anderson, Kimberly M. L. May, Leonidas G. Bachas
Abstract: This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin1 and the amplification of Pin1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.
Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.
Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.
Type:
Grant
Filed:
November 22, 2006
Date of Patent:
September 8, 2009
Assignee:
Corixa Corporation
Inventors:
Tongtong Wang, Robert A. Henderson, Teresa M. Foy
Abstract: The present invention stems from the realization that the cell surface content of sialic acids is associated with drug susceptibility and resistance in neoplastic and damaged cells. A general decrease in the amounts of the ?2-6 linked sialic acid has been confirmed in resistant phenotype compare to its corresponding sensitive parental cells. Treating the resistant phenotype with neuraminidase, an enzyme that removes the sialic acid from the sugar chain, facilitates the drug internalization and reinstalls the cell susceptibility to the drug. Based on these observations, methods for predicting the resistance to a number of drugs and detecting multi-drug resistanc in neoplastic and damaged cells have been invented.
Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
Type:
Grant
Filed:
August 30, 2002
Date of Patent:
September 1, 2009
Assignees:
Elan Pharma International Limited, Wyeth